These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817 [TBL] [Abstract][Full Text] [Related]
4. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522 [TBL] [Abstract][Full Text] [Related]
5. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325 [TBL] [Abstract][Full Text] [Related]
6. A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD. Hu H; Zhang L; Teng G; Wu Y; Chen Y Int J Chron Obstruct Pulmon Dis; 2015; 10():1641-9. PubMed ID: 26316738 [TBL] [Abstract][Full Text] [Related]
7. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149 [TBL] [Abstract][Full Text] [Related]
8. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416 [TBL] [Abstract][Full Text] [Related]
9. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Ganzinelli M; Rulli E; Caiola E; Garassino MC; Broggini M; Copreni E; Piva S; Longo F; Labianca R; Bareggi C; Fabbri MA; Martelli O; Fagnani D; Locatelli MC; Bertolini A; Valmadre G; Pavese I; Calcagno A; Sarobba MG; Marabese M Sci Rep; 2015 Nov; 5():16331. PubMed ID: 26573509 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population. Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004 [TBL] [Abstract][Full Text] [Related]
11. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714 [TBL] [Abstract][Full Text] [Related]
12. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer. De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer. Xu J; Tian S; Yin Z; Wu S; Liu L; Qian Y; Pei D; Gao W; Xu J; Yin Y; Liu P; Shu Y Lung Cancer; 2014 Sep; 85(3):442-8. PubMed ID: 24997136 [TBL] [Abstract][Full Text] [Related]
14. Variant SNPs at the microRNA complementary site in the B7‑H1 3'‑untranslated region increase the risk of non‑small cell lung cancer. Du W; Zhu J; Chen Y; Zeng Y; Shen D; Zhang N; Ning W; Liu Z; Huang JA Mol Med Rep; 2017 Sep; 16(3):2682-2690. PubMed ID: 28677815 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis. Farahani MS; Shahbazi S; Moghaddam SA; Mahdian R Reprod Sci; 2015 Jun; 22(6):679-84. PubMed ID: 25361550 [TBL] [Abstract][Full Text] [Related]
16. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy. Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918 [TBL] [Abstract][Full Text] [Related]
17. Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer. Huang X; Yang Y; Guo Y; Cao ZL; Cui ZW; Hu TC; Gao LB Genet Mol Res; 2015 Dec; 14(4):16913-20. PubMed ID: 26681038 [TBL] [Abstract][Full Text] [Related]
18. A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer. Li ZH; Pan XM; Han BW; Guo XM; Zhang Z; Jia J; Gao LB Tumour Biol; 2013 Oct; 34(5):3159-63. PubMed ID: 23729275 [TBL] [Abstract][Full Text] [Related]
19. No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis. Luong HT; Nyholt DR; Painter JN; Chapman B; Kennedy S; Treloar SA; Zondervan KT; Montgomery GW Hum Reprod; 2012 Dec; 27(12):3616-21. PubMed ID: 23010532 [TBL] [Abstract][Full Text] [Related]
20. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis. Langevin SM; Christensen BC Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]